REX launches peptide ETF reaching beyond GLP-1 drugmakers
The fund targets peptide therapeutics broadly rather than concentrating in the incretin names that dominate existing obesity-themed products.
TR
By Tom Reyes · Markets Editor
Oct 14 11:51 ETSource: ETF Database
The wire
- 01REX introduced an exchange-traded fund built around peptide therapeutics, positioned to hold more than the GLP-1 manufacturers that anchor obesity-focused funds.
- 02A dedicated vehicle signals that capital markets are starting to treat peptides as a distinct therapeutic category rather than a GLP-1 subplot.
- 03Holdings, fee structure and index methodology are not detailed here, and a fund launch says nothing about the clinical prospects of the underlying assets.
From the source
Read at etfdb.comNew Peptide ETF From REX Looks Beyond GLP-1 Drugs
